Lead Product(s) : Lopinavir,Ritonavir
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase I
Sponsor : Daré Bioscience
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Douglas Pharmaceuticals Secures US licensing Deal to Treat High Grade Cervical Dysplasia
Details : Under the license agreement with Douglas, Dare will be responsible for advancing the development of R-131-2 (Lopinavir/Ritonavir) in the U.S. for the treatment for cervical intraepithelial neoplasia.
Brand Name : R-131-2
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 27, 2023
Lead Product(s) : Lopinavir,Ritonavir
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase I
Sponsor : Daré Bioscience
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Lopinavir,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
AbbVie’s HIV drug combo shows no benefit in Covid-19 trial
Details : The primary endpoint was the time to clinical improvement. The medication failed to improve the condition or prevent the death of severely-affected Covid-19 patients, compared to standard care.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 19, 2020
Lead Product(s) : Lopinavir,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Lopinavir,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : European Health Authorities
Deal Size : Undisclosed
Deal Type : Partnership
AbbVie Partnering with Global Authorities
Details : The company is collaborating with select health authorities and institutions globally to determine antiviral activity as well as efficacy and safety of lopinavir/ritonavir against COVID-19.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 09, 2020
Lead Product(s) : Lopinavir,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : European Health Authorities
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Lopinavir,Ritonavir
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase I
Sponsor : ARPA-H
Deal Size : $10.0 million
Deal Type : Funding
Daré Bioscience Wins $10M Award from ARPA-H for Women’s Health
Details : The funding will be used to advance DARE-HPV, a potential first-in-category treatment for human papillomavirus (HPV)-related cervical disease.
Brand Name : DARE-HPV
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 23, 2024
Lead Product(s) : Lopinavir,Ritonavir
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase I
Sponsor : ARPA-H
Deal Size : $10.0 million
Deal Type : Funding
Lead Product(s) : Abacavir,Lamivudine,Lopinavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The ‘4-in-1’ combination contains an antiretroviral combination of Abacavir, as an alternative first-line regimen for infants and young children with HIV – in the form of granule-filled capsules.
Brand Name : ABC/3TC/LPV/r
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 14, 2022
Lead Product(s) : Abacavir,Lamivudine,Lopinavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Albuvirtide,Lopinavir,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The results of the randomized controlled, open-labelled, multicenter, non-inferiority study showed successful achievement of the primary endpoint, with a good proportion of patients on the ABT regimen with HIV RNA less than 50 copies/mL at 48 weeks.
Brand Name : Aikening
Molecule Type : Peptide
Upfront Cash : Not Applicable
July 19, 2021
Lead Product(s) : Albuvirtide,Lopinavir,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Azithromycin,Lopinavir,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
RECOVERY Trial Finds No Benefit from Azithromycin in Patients Hospitalised with Covid-19
Details : A preliminary analysis shows no significant difference in the primary endpoint of 28-day mortality (19% azithromycin vs. 19% usual care) There was also no evidence of beneficial effects on the risk of progression to mechanical ventilation or length of ho...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 14, 2020
Lead Product(s) : Azithromycin,Lopinavir,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Lopinavir,Ritonavir,Hydroxychloroquine Sulphate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inserm-ANRS
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The trial will begin testing, against a control arm, the HIV antiretroviral combination lopinavir/ritonavir with a loaded dose and the malaria drug hydroxychloroquine, which remains the standard of care for COVID-19 today in numerous African countries.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 24, 2020
Lead Product(s) : Lopinavir,Ritonavir,Hydroxychloroquine Sulphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inserm-ANRS
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Remdesivir,Lopinavir,Hydroxychloroquine Sulphate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : World Health Organization
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Interim data from the WHO-coordinated Solidarity Therapeutics Trial suggest that remdesivir, hydroxychloroquine, lopinavir / ritonavir, and interferon regimens in COVID patients have little or no impact on 28-day mortality or the in-hospital course of CO...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 15, 2020
Lead Product(s) : Remdesivir,Lopinavir,Hydroxychloroquine Sulphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : World Health Organization
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Lopinavir,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The trial Steering Committee concluded that there is no beneficial effect of lopinavir-ritonavir in patients hospitalised with COVID-19 and closed randomisation to that treatment arm.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 29, 2020
Lead Product(s) : Lopinavir,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.
